Anthem Biosciences IPO open date is July 14, 2025 and the IPO will close on July 16, 2025.
The company reported revenue of ₹1,930.29 crores and profit of ₹451.26 crores in 2025.
Anthem Biosciences Limited was originally incorporated as “Anthem Biosciences Private Limited” on June 13, 2006. The company transitioned to a public limited company in 2024. Headquartered in Bangalore, it has evolved into a global CRDMO (Contract Research, Development, and Manufacturing Organization) offering integrated services for both small and large molecules, catering to over 500 clients worldwide.
Anthem Biosciences IPO Details
| IPO Open Date: | July 14, 2025 |
| IPO Close Date: | July 16, 2025 |
| Face Value: | ₹2 Per Equity Share |
| IPO Price Band: | ₹540 to ₹570 Per Share |
| Issue Size: | Approx ₹3,395 Crores |
| Offer for Sale: | Approx 5,95,61,404 Equity Shares |
| Issue Type: | Book Build Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
Anthem Biosciences IPO Market Lot
The Anthem Biosciences IPO minimum market lot is 26 shares with ₹14,820 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 26 | ₹14,820 |
| Retail Maximum | 13 | 338 | ₹1,92,660 |
| S-HNI Minimum | 14 | 364 | ₹2,07,480 |
| B-HNI Minimum | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹1,280.24 | ₹734.10 | ₹405.54 | ₹1,618.87 |
| 2023 | ₹1,133.99 | ₹698.50 | ₹385.19 | ₹2,014.46 |
| 2024 | ₹1,483.07 | ₹1,005.75 | ₹367.31 | ₹2,398.11 |
| 2025 | ₹1,930.29 | ₹1,273.42 | ₹451.26 | ₹2,807.58 |
Anthem Biosciences IPO Valuation – FY2025
Check Anthem Biosciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 20.82% |
| ROCE: | 27.64% |
| EBITDA Margin: | 36.81% |
| PAT Margin: | 23.38% |
| Debt to equity ratio: | 0.05 |
| Earning Per Share (EPS): | ₹8.07 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 20.82% |
| Net Asset Value (NAV): | ₹43.10 |
About Anthem Biosciences
- Incorporated on June 13, 2006, as “Anthem Biosciences Private Limited” in Bangalore, Karnataka.
- Converted into a public company on October 18, 2024, and renamed “Anthem Biosciences Limited”.
- Key milestones:
- 2007: Commenced operations with a custom synthesis plant.
- 2013–2025: Achieved multiple USFDA and international regulatory approvals.
- 2020–2025: Expanded operations to Units II and III, added advanced capabilities like continuous flow manufacturing and fermentation scale-up.
- Owns subsidiary Neoanthem Lifesciences Private Limited.
- Developed a wide range of innovative biomanufacturing solutions including ADCs, RNAi, and glycolipid-based platforms.
Business Overview
Anthem Biosciences generates revenues through CRDMO services for both small molecules and biologics. These include discovery, development, scale-up, and manufacturing. Around 70.8% of revenue comes from manufacturing and development, while 10.9% comes from R&D services.
The company has advanced capabilities such as RNAi delivery systems, ADC platforms, and continuous flow chemistry. Anthem caters to regulated and semi-regulated markets including the US, Europe, and Asia.
- Core business: CRDMO (Contract Research, Development, and Manufacturing Organization) services.
- Services offered: Spanning drug discovery to commercial manufacturing for both small and large molecules (biologics).
- Revenue Mix FY25:
- R&D Services: 10.9%
- Development and Manufacturing: 70.8%
- Clients: 500+ across global regulated and semi-regulated markets.
- Technologies:
- Flow chemistry, biotransformation, pincer catalysis, ADC, RNAi delivery platforms.
- Sustainability:
- 90% energy from renewable sources.
- Lowest GHG emission intensity among Indian CRDMO peers.
Industry & Market Overview
- The CRDMO market is projected to grow at a CAGR of 13.5%, reaching USD 21.4 billion by 2029.
- Anthem operates in regulated (e.g., US, Europe, Japan) and semi-regulated markets.
- Competitive Advantages:
- Largest fermentation capacity among Indian peers (182 KL by FY26).
- Integrated capabilities across drug lifecycle and molecule types (NCEs & NBEs).
- Pioneer in India for biologics, enzymatic synthesis, and green chemistry.
- Competes with peers like Syngene, Divi’s Labs, and global players such as Wuxi AppTec and Lonza.
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Syngene International Limited | 12.35 | 51.54 | 11.05% | 117.42 | 3,642.40 Cr. |
| Sai Life Sciences Limited | 8.83 | 92.18 | 10.96% | 102.12 | 1,694.57 Cr. |
| Suven Life Sciences Limited | 10.52 | 97.29 | 13.61% | 72.31 | 1,197.58 Cr. |
| Divi’s Laboratories Limited | 82.53 | 83.22 | 15.35% | 564.87 | 9,360.00 Cr. |
Objects of the Issue
- The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
Anthem Biosciences IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: anthem.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
IPO Lead Managers aka Merchant Bankers
- Jm Financial Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Company Address
Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/
Anthem Biosciences IPO FAQs
What does Anthem Biosciences do?
It is a contract research, development, and manufacturing organization (CRDMO) offering end-to-end pharma/biotech services.
When Anthem Biosciences IPO will open for subscription?
The IPO is to open on July 14, 2025 for QIB, NII, and Retail Investors. The IPO will close on July 16, 2025.
What is Anthem Biosciences IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
What is Anthem Biosciences IPO Issue Size?
Anthem Biosciences IPO issue size is ₹3,395 crores.
What is Anthem Biosciences IPO Price Band?
Anthem Biosciences IPO Price Band is ₹540 to₹570.
What is Anthem Biosciences IPO Lot Size?
The minimum bid is 26 Shares with ₹14,820 amount.
What is the Anthem Biosciences IPO Allotment Date?
Anthem Biosciences IPO allotment date is July 17, 2025.
What is the Anthem Biosciences IPO Listing Date?
Anthem Biosciences IPO listing date is July 21, 2025. The IPO is to list on BSE & NSE.